AMGN - Amgen Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—General
Thousand Oaks,
United States
Type: Equity
AMGN price evolution
AMGN
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $9301 | $9708 | $10944 | |
| Short term investments | ||||
| Net receivables | $7317 | $6934 | $6776 | $7268 |
| Inventory | $7362 | $7995 | $8724 | $9518 |
| Total current assets | $26766 | $27206 | $28029 | $30332 |
| Long term investments | ||||
| Property, plant & equipment | $6156 | $6097 | $6002 | $5941 |
| Goodwill & intangible assets | $48788 | $49942 | $51270 | |
| Total noncurrent assets | $63701 | $64951 | $66822 | |
| Total investments | ||||
| Total assets | $90883 | $90907 | $92980 | $97154 |
| Current liabilities | ||||
| Accounts payable | $18915 | $2267 | $1628 | $1590 |
| Deferred revenue | ||||
| Short long term debt | $5528 | $3959 | $1443 | |
| Total current liabilities | $20312 | $21517 | $19714 | $18392 |
| Long term debt | $56854 | $57117 | $60061 | $63170 |
| Total noncurrent liabilities | $63465 | $68244 | $72530 | |
| Total debt | $62645 | $64020 | $64613 | |
| Total liabilities | $83356 | $84982 | $87958 | $90922 |
| Shareholders' equity | ||||
| Retained earnings | -$25530 | -$27124 | -$27870 | -$26549 |
| Other shareholder equity | -$336 | -$155 | -$190 | -$289 |
| Total shareholder equity | $5925 | $5022 | $6232 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10944 | $7629 | $7989 | $6266 |
| Short term investments | $1676 | $48 | $4381 | |
| Net receivables | $7268 | $5563 | $4895 | $4525 |
| Inventory | $9518 | $4930 | $4086 | $3893 |
| Total current assets | $30332 | $22186 | $19385 | $21144 |
| Long term investments | $1176 | |||
| Property, plant & equipment | $5941 | $5427 | $5184 | $4889 |
| Goodwill & intangible assets | $51270 | $31609 | $30072 | $31276 |
| Total noncurrent assets | $66822 | $42935 | $41780 | $41804 |
| Total investments | $1676 | $48 | $4381 | |
| Total assets | $97154 | $65121 | $61165 | $62948 |
| Current liabilities | ||||
| Accounts payable | $1590 | $14096 | $1366 | $1421 |
| Deferred revenue | ||||
| Short long term debt | $1443 | $1591 | $87 | $91 |
| Total current liabilities | $18392 | $15687 | $12184 | $11653 |
| Long term debt | $63170 | $37354 | $33222 | $32895 |
| Total noncurrent liabilities | $72530 | $45773 | $42281 | $41886 |
| Total debt | $64613 | $38945 | $33309 | $32986 |
| Total liabilities | $90922 | $61460 | $54465 | $53539 |
| Shareholders' equity | ||||
| Retained earnings | -$26549 | -$28622 | -$24600 | -$21408 |
| Other shareholder equity | -$289 | $3661 | -$796 | -$985 |
| Total shareholder equity | $6232 | $3661 | $6700 | $9409 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8503 | $8388 | $7447 | |
| Cost of revenue | $3236 | $3200 | ||
| Gross Profit | $5193 | $5152 | $4247 | |
| Operating activities | ||||
| Research & development | $1447 | $1343 | ||
| Selling, general & administrative | $1785 | $1808 | ||
| Total operating expenses | $3146 | $3243 | $3256 | |
| Operating income | $1909 | $991 | ||
| Income from continuing operations | ||||
| EBIT | $1602 | $756 | ||
| Income tax expense | $271 | $48 | $45 | |
| Interest expense | $943 | $808 | $824 | |
| Net income | ||||
| Net income | $2830 | $746 | -$113 | |
| Income (for common shares) | $746 | -$113 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $28190 | $26323 | $25979 | $25424 |
| Cost of revenue | $8451 | $6406 | $6454 | $6159 |
| Gross Profit | $19739 | $19917 | $19525 | $19265 |
| Operating activities | ||||
| Research & development | $4784 | $4434 | $4819 | $4207 |
| Selling, general & administrative | $6179 | $5414 | $5368 | $5730 |
| Total operating expenses | $11842 | $10351 | $11886 | $10126 |
| Operating income | $7897 | $9566 | $7639 | $9139 |
| Income from continuing operations | ||||
| EBIT | $10730 | $8752 | $7898 | $9395 |
| Income tax expense | $1138 | $794 | $808 | $869 |
| Interest expense | $2875 | $1406 | $1197 | $1262 |
| Net income | ||||
| Net income | $6717 | $6552 | $5893 | $7264 |
| Income (for common shares) | $6717 | $6552 | $5893 | $7264 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $746 | -$113 | $767 | |
| Operating activities | ||||
| Depreciation | $1400 | $1399 | $1380 | |
| Business acquisitions & disposals | -$26989 | |||
| Stock-based compensation | $157 | $103 | $431 | |
| Total cash flows from operations | $2459 | $689 | $538 | |
| Investing activities | ||||
| Capital expenditures | -$238 | -$230 | -$249 | |
| Investments | -$2 | |||
| Total cash flows from investing | -$644 | -$217 | -$217 | -$27089 |
| Financing activities | ||||
| Dividends paid | -$3627 | -$1209 | -$1208 | -$1140 |
| Sale and purchase of stock | ||||
| Net borrowings | -$1400 | -$410 | $3899 | |
| Total cash flows from financing | -$8008 | -$2649 | -$1708 | $2754 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1933 | -$407 | -$1236 | -$23797 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $6717 | $6552 | $5893 | $7264 |
| Operating activities | ||||
| Depreciation | $4071 | $3417 | $3398 | $3601 |
| Business acquisitions & disposals | -$26989 | -$3709 | -$2529 | |
| Stock-based compensation | $431 | $401 | $341 | $330 |
| Total cash flows from operations | $8471 | $9721 | $9261 | $10497 |
| Investing activities | ||||
| Capital expenditures | -$1112 | -$936 | -$880 | -$608 |
| Investments | $1672 | -$1387 | $4177 | -$4718 |
| Total cash flows from investing | -$26204 | -$6044 | $733 | -$5401 |
| Financing activities | ||||
| Dividends paid | -$4556 | -$4196 | -$4013 | -$3755 |
| Sale and purchase of stock | -$6360 | -$4975 | -$3486 | |
| Net borrowings | $25676 | $6622 | $795 | $2464 |
| Total cash flows from financing | $21048 | -$4037 | -$8271 | -$4867 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $3315 | -$360 | $1723 | $229 |
News
Fundamentals
| Market cap | $146.97B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 537.50M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 23.18% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 14.59 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.32 |
| Quick ratio | 0.96 |